The global diabetes care market is experiencing unprecedented growth, with projections indicating expansion from $34.51 billion in 2025 to $62.73 billion by 2032, according to a comprehensive market analysis by Coherent Market Insights. This represents a robust compound annual growth rate (CAGR) of 8.9% over the forecast period.
Market Drivers and Disease Burden
The alarming rise in diabetes cases worldwide serves as the primary catalyst for market growth. According to the International Diabetes Federation, approximately 589 million adults are currently living with diabetes, with projections indicating this number will reach 853 million by 2045. This escalation is driven by factors including an aging population and the adoption of unhealthy dietary habits.
Type 2 diabetes dominates the market landscape, accounting for nearly two-thirds of the global diabetes care market share in 2025. The Type 2 diabetes market specifically is valued at $43.02 billion in 2025 and is projected to reach $73.31 billion by 2032, growing at a CAGR of 7.9%.
Technology Segment Performance
Glucose monitoring devices represent the largest product segment, expected to generate approximately $16.46 billion in revenue in 2025. This growth is attributed to high adoption rates of these devices for improving diabetes management efficiency. Continuous glucose monitoring (CGM) devices are particularly gaining traction due to their accuracy and real-time monitoring capabilities, gradually replacing traditional blood glucose meters.
The shift toward personalized diabetes management is prompting companies to develop tailored treatment plans using genomic profiling and patient-specific data. Technological advancements are revolutionizing the industry, with companies continuously developing smart insulin pens, continuous glucose monitors, and AI-powered diabetes applications.
Strategic Partnerships and Innovation
Leading manufacturers are focusing on creating automated insulin delivery systems that can automatically adjust insulin doses based on CGM readings. A notable example is the August 2024 partnership between Abbott and Medtronic to develop an integrated CGM system based on Abbott's advanced FreeStyle Libre Technology, designed to connect with Medtronic's automated insulin delivery and smart insulin pen systems.
Recent regulatory approvals highlight continued innovation in the space. In August 2024, Medtronic received U.S. FDA approval for its Simplera CGM, the company's first disposable, all-in-one CGM designed to be half the size of previous Medtronic CGMs. Additionally, in March 2025, Insulet Corporation announced expansion of its Omnipod 5 Automated Insulin Delivery System to four international markets, including Australia, Belgium, Canada, and Switzerland.
Market Challenges and Opportunities
Despite optimistic growth projections, several factors may limit market expansion. High costs of advanced diabetes care technologies, including insulin pumps and continuous glucose monitors, deter adoption, particularly in low- and middle-income nations. Product recalls are also becoming more frequent, eroding consumer trust. Notable examples include Roche's May 2024 recall of certain AccuChek Guide blood glucose meters and Abbott's July 2024 recall of FreeStyle Libre 2 sensors due to health risks.
However, rising awareness and early diagnosis initiatives create significant growth opportunities. Governments and healthcare organizations worldwide are launching awareness campaigns to educate people about diabetes, its risk factors, early symptoms, and treatment options, which is expected to enhance early diagnosis rates and drive demand for monitoring and treatment devices.
Regional Market Dynamics
North America is positioned to retain its market dominance, accounting for approximately $14.87 billion in revenue in 2025. However, Asia Pacific is set to witness the fastest growth rate during the assessment period, attributed to increasing diabetic population and improved access to diabetic care devices and services.
End-User Segmentation
Hospitals and clinics represent the dominant end-user category, holding a 54.7% revenue share in 2025. However, the homecare settings segment is experiencing significant growth, valued at $19.5 billion by 2025 for the Type 2 diabetes market, reflecting the shift toward self-monitoring and home-based diabetes management.
Senior analyst Manisha Vibhute noted, "The future of diabetes care market looks bright, considering the increasing diabetes prevalence globally and advancements in diabetic care products. Shift towards homecare and self-monitoring is expected to lead to a higher demand for home-based diabetes management devices in the coming years."
The market's trajectory reflects the critical need for innovative diabetes management solutions as the global burden of this chronic condition continues to escalate, positioning the diabetes care industry for sustained growth through technological advancement and improved patient access to care.
